SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage. The company offers MucoPEG, a medical device for treatment of dry mouth syndrome; and SynoGEL, a viscosupplement for arthritic Knee. Its preclinical stage biopharmaceuticals candidates target brain stroke and chronic anemia. It also manufactures and sells PEG derivatives. The company was founded in 1997 and is headquartered in Gunpo-si, South Korea.
Metrics to compare | 067370 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship067370PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.1x | −0.5x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price/Book | 0.0x | 2.6x | 2.6x | |
Price / LTM Sales | 0.0x | 9.0x | 3.3x | |
Upside (Analyst Target) | 0.0% | 25.5% | 43.4% | |
Fair Value Upside | Unlock | 1.7% | 7.1% | Unlock |